Literature DB >> 21303836

'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010.

M L Bertolaccini1, O Amengual, T Atsumi, W L Binder, B de Laat, R Forastiero, W H Kutteh, M Lambert, H Matsubayashi, V Murthy, M Petri, J H Rand, M Sanmarco, A E Tebo, S S Pierangeli.   

Abstract

Abstract: Current classification criteria for definite APS recommend the use of one or more of three positive standardized laboratory assays, including anticardiolipin antibodies (aCL), lupus anticoagulant (LA), and antibodies directed to β(2)glycoprotein I (anti-β(2)GPI) to detect antiphospholipid antibodies (aPL) in the presence of at least one of the two major clinical manifestations (i.e., thrombosis or pregnancy morbidity) of the syndrome. Several other autoantibodies shown to be directed to phospholipids and/or their complexes with phospholipids and/or to proteins of the coagulation cascade, as well as a mechanistic test for resistance to annexin A5 anticoagulant activity, have been proposed to be relevant to APS. A task force of worldwide scientists in the field discussed and analyzed critical questions related to 'non-criteria' aPL tests in an evidence-based manner during the 13th International Congress on Antiphospholipid Antibodies (APLA 2010, 13-16 April 2010, Galveston, Texas, USA). This report summarizes the findings, conclusions, and recommendations of this task force.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21303836     DOI: 10.1177/0961203310397082

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  37 in total

Review 1.  Antiphospholipid syndrome: laboratory testing and diagnostic strategies.

Authors:  Thomas L Ortel
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

2.  Comparative analysis of different enzyme immunoassays for assessment of phosphatidylserine-dependent antiprothrombin antibodies.

Authors:  Olga Amengual; Tetsuya Horita; Walter Binder; Gary L Norman; Zakera Shums; Masaru Kato; Kotaro Otomo; Yuichiro Fujieda; Kenji Oku; Toshiyuki Bohgaki; Shinsuke Yasuda; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2014-02-05       Impact factor: 2.631

3.  New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies.

Authors:  Savino Sciascia; Munther A Khamashta; Maria Laura Bertolaccini
Journal:  Curr Rheumatol Rep       Date:  2014-05       Impact factor: 4.592

4.  Differential assay reactivity of immunglobulin A anti-ß2 glycoprotein I antibodies: implications for the clinical interpretation of antiphospholipid antibody testing.

Authors:  David B Hood; Karin R Snyder; Tammy R Buckner; Beth L Hurley; Kelly R Pitts; Luis R Lopez
Journal:  Eur J Rheumatol       Date:  2015-08-21

Review 5.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

6.  Inactive disease and remission in childhood-onset systemic lupus erythematosus.

Authors:  Rina Mina; Marisa S Klein-Gitelman; Angelo Ravelli; Michael W Beresford; Tadej Avcin; Graciela Espada; B Anne Eberhard; Laura E Schanberg; Kathleen M O'Neil; Clovis A Silva; Gloria C Higgins; Karen Onel; Nora G Singer; Emily von Scheven; Lisa F Imundo; Shannen Nelson; Edward H Giannini; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

7.  The outcome of ELISA for antiphosphatidylethanolamine antibodies is dependent on the composition of phosphatidylethanolamine.

Authors:  Songwang Hou; Paul E Harper; Nathalie Bardin; Ming Zhao
Journal:  J Immunol Methods       Date:  2016-10-23       Impact factor: 2.303

Review 8.  The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome.

Authors:  Rohan Willis; E B Gonzalez; A R Brasier
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

9.  Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome.

Authors:  Vijaya Murthy; Rohan Willis; Zurina Romay-Penabad; Patricia Ruiz-Limón; Laura A Martínez-Martínez; Shraddha Jatwani; Praveen Jajoria; Alan Seif; Graciela S Alarcón; Elizabeth Papalardo; Jigna Liu; Luis M Vilá; Gerald McGwin; Terry A McNearney; Rashmi Maganti; Prashanth Sunkureddi; Trisha Parekh; Michael Tarantino; Ehtisham Akhter; Hong Fang; Emilio B Gonzalez; Walter R Binder; Gary L Norman; Zakera Shums; Marius Teodorescu; John D Reveille; Michelle Petri; Silvia S Pierangeli
Journal:  Arthritis Rheum       Date:  2013-12

Review 10.  Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies.

Authors:  Laura Andreoli; Micaela Fredi; Cecilia Nalli; Silvia Piantoni; Rossella Reggia; Francesca Dall'Ara; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.